Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study to Evaluate Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections

This study has been completed.
Information provided by (Responsible Party):
Insmed Incorporated Identifier:
First received: March 14, 2011
Last updated: February 12, 2015
Last verified: February 2015

March 14, 2011
February 12, 2015
March 2012
June 2013   (final data collection date for primary outcome measure)
Relative change in Forced Expiratory Volume in 1 second (FEV1) from baseline to end of study (Day 168) [ Time Frame: 168 days ] [ Designated as safety issue: Yes ]
Same as current
Complete list of historical versions of study NCT01315678 on Archive Site
  • Changes in pulmonary function throughout the study [ Time Frame: 168 days ] [ Designated as safety issue: Yes ]
  • Time to and proportion of subjects experiencing a pulmonary exacerbation [ Time Frame: 168 days ] [ Designated as safety issue: Yes ]
  • Time to first antipseudomonal antibiotic treatment for pulmonary exacerbation [ Time Frame: 168 days ] [ Designated as safety issue: Yes ]
  • Time to and number of hospitalizations [ Time Frame: 168 days ] [ Designated as safety issue: Yes ]
  • Change in density in Pseudomonas aeruginosa in sputum [ Time Frame: 168 days ] [ Designated as safety issue: Yes ]
  • Change in patient reported outcomes/symptoms [ Time Frame: 168 days ] [ Designated as safety issue: Yes ]
  • Evaluation of safety and tolerability [ Time Frame: 168 days ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
Study to Evaluate Arikace™ in CF Patients With Chronic Pseudomonas Aeruginosa Infections
Randomized, Open-Label, Active-Controlled, Multicenter Study to Assess the Efficacy, Safety and Tolerability of Arikace™ in Cystic Fibrosis Patients With Chronic Infection Due to Pseudomonas Aeruginosa

A major factor in the respiratory health of Cystic Fibrosis (CF) subjects is the prevalence of chronic Pseudomonas aeruginosa infections. The Pseudomonas aeruginosa infection rate in CF patients increases with age and by age 18 years approximately 85% of CF patients in the US are infected. Liposomal amikacin for inhalation (Arikace™) was developed as a possible treatment for chronic infection due to Pseudomonas aeruginosa in CF patients.

The purpose of this European Registration study is to determine whether Arikace™ is effective in treating chronic lung infections caused by Pseudomonas aeruginosa in Cystic Fibrosis subjects. The effectiveness, safety and tolerability of Arikace™ will be compared to TOBI, an inhalation antibiotic already available for use. The study will enroll approximately 300 subjects in clinics in Europe and Canada. Subjects will be required to visit the clinic 9 times (including the Screening visit) over a period of approximately 6 months. No overnight stays at the clinic will be required.

Cystic Fibrosis (CF) is a genetic disease resulting from mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Patients with CF manifest pathological changes in a variety of organs that express CFTR. The lungs are frequently affected often resulting in chronic infections by bacteria such as Pseudomonas aeruginosa and airway inflammation. Treatment of chronic lung infections is one of the principal goals of CF therapy. Arikace™ (liposomal amikacin for inhalation) is a sustained-release formulation of amikacin encapsulated inside nanoscale liposomal carriers designed for administration via inhalation. It is hypothesized that the sustained-release pulmonary targeting and biofilm penetration properties of this formulation will have several advantages over current therapies in treating CF patients with chronic lung infection caused by Pseudomonas aeruginosa.

This Phase 3 European Registration study has been designed to evaluate the efficacy, safety and tolerability of Arikace™ in treating CF patients with chronic bronchopulmonary infection compared to a currently available antibiotic, TOBI® (tobramycin) Inhalation Solution. Eligible subjects will be randomized 1:1 to receive 590 mg of Arikace™ once daily via a PARI Investigational eFlow® Nebulizer or 300 mg TOBI® BID via a PARI LC® PLUS nebulizer. Subjects will receive 3 cycles of treatment with each cycle being comprised of 28 days on treatment followed by 28 days off-treatment. Total study duration is up to 186 days (~6 months) including an up to 18 day Screening period. Subjects will be evaluated for safety, tolerability and efficacy bi-weekly during the first 4 weeks of treatment, and thereafter every 4 weeks for the duration of the study. Pharmacokinetics (PK) of Arikace™ in blood, sputum and 24-hour urine will be determined in a subgroup of study subjects who consent to PK evaluation.

At the completion of the TR02-108 protocol, subjects who have consented and meet study safety criteria may enroll in the long-term, open-label, multi-cycle extension study of 590 mg of Arikace™ (under a separate protocol TR02-110).

Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Cystic Fibrosis
  • Drug: Liposomal amikacin for inhalation
    • Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
    • 590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
    • Administration time is approximately 13 minutes.
    • Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment.
  • Drug: Tobramycin inhalation solution
    • 300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
    • Nebulization time is approximately 20 minutes for each administration.
    • Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment
  • Experimental: Arikace™
    Arikace™ is liposomal amikacin for inhalation
    Intervention: Drug: Liposomal amikacin for inhalation
  • Active Comparator: TOBI®
    TOBI® is tobramycin inhalation solution
    Intervention: Drug: Tobramycin inhalation solution
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2013
June 2013   (final data collection date for primary outcome measure)

Key Inclusion Criteria:

  • Written informed consent or assent
  • Confirmed diagnosis of CF
  • History of chronic infection with Pseudomonas aeruginosa
  • Sputum culture positive for Pseudomonas aeruginosa at Screening
  • FEV1 ≥ 25% of predicted value at Screening

Key Exclusion Criteria:

  • FEV1 <25% of predicted at Screening
  • History of major complications of lung disease within 8 weeks prior to Screening
  • Hemoptysis of ≥60 mL in a 24-hour period within 4 weeks prior to Screening
  • History of positive culture for Burkholderia cepacia within 2 years prior to Screening
  • History of pulmonary tuberculosis or non-tuberculous mycobacterial lung disease treated within 2 years prior to Screening or requiring treatment at the time of screening
  • History of Allergic Broncho-Pulmonary Aspergillosis or any other condition requiring systemic steroids at a dose ≥ equivalent of 10 mg/day of prednisone within 3 months prior to Screening
  • Presence of any clinically significant cardiac disease
  • History of lung transplantation
  • Daily, continuous oxygen supplementation or nighttime supplemental oxygen requirement of greater than 2 L/min
  • Administration of any investigational products within 8 weeks prior to study Day 1
  • Smoking tobacco or any substance within 6 months prior to screening or anticipated inability to refrain from smoking throughout the study
6 Years and older
Contact information is only displayed when the study is recruiting subjects
Austria,   Belgium,   Bulgaria,   Canada,   Denmark,   France,   Germany,   Greece,   Hungary,   Ireland,   Italy,   Netherlands,   Poland,   Serbia,   Slovakia,   Spain,   Sweden,   United Kingdom
Insmed Incorporated
Insmed Incorporated
Not Provided
Study Director: Gina Eagle, MD Insmed Incorporated
Insmed Incorporated
February 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP